ClinicaliQ Trial Snapshot
- Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition — Recruiting • Oncology • NCT06409585.
- What is being tested: Advanced cardiac imaging techniques to detect and evaluate myocardial fibrosis progression in patients with cardiomyopathies and heart muscle diseases, focusing on transitional fibrosis patterns that may predict clinical deterioration.
- Patient eligibility overview: Individuals diagnosed with or suspected of having cardiomyopathies and heart muscle diseases where myocardial fibrosis assessment is clinically indicated; specific eligibility criteria would include confirmed or suspected cardiomyopathy diagnosis requiring imaging characterisation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and…
Eligibility Snapshot
- : HFpEF cohort * Male or female between 30 to 90 years old * Provision of informed consent prior to any study specific procedures * Patients with symptomatic heart failure with preserved ejection fraction as defined by the presence of heart failure symptoms (dyspnoea, reduced exercise tolerance, fatigue), signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) as well as echocardiographic features (preserved left ventricular systolic function (>50%) and reduced diastolic function with septal e'
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.